Irene B. Helenowski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Irene B. Helenowski has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Seema Ahsan Khan
12Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois
11 shared publications Borko D. Jovanovic
9 shared publications- Robert Treat Chatterton
Department of Obstetrics and Gynecology, Physiology and Pathology, Feinberg School of Medicine, Northwestern University
9 shared publications - Adrian A. Franke
University of Hawaii Cancer Center, University of Hawaii at Manoa, 701 Ilalo Street, Honolulu, HI 96813, USA
8 shared publications Alexander Dew
8 shared publicationsCarola M. Zalles
8 shared publications
Latest Publications
- 17 December 2023
- Published by Elsevier in The American Journal of Surgery
- Vol. 229, 133-139
Is state trauma funding associated with mortality among injured hospitalized patients?
- 17 December 2023
- Published by Elsevier in The American Journal of Surgery
- Vol. 229, 133-139
Is state trauma funding associated with mortality among injured hospitalized patients?
- Open Access
- 30 June 2023
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 29 (1) , 47-56
Phase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non–Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175
Combination chemotherapy and immunotherapy regimens have significantly improved survival for patients with previously untreated advanced non–small cell lung cancer (NSCLC). Improvements in overall survival (OS) in two separate pembrolizumab trials have demonstrated survival improvements over chemotherapy alone, regardless of PD-L1 status. The optimal chemotherapy backbone for combination with immunotherapy is unknown. We hypothesized nab-paclitaxel may be a well-suited platinum partner to use in combination with checkpoint inhibitor therapy for both adenocarcinoma and squamous histology and conducted a phase I/II trial to assess the efficacy of this regimen in advanced NSCLC. Adult patients with previously untreated, stage IIIB/IV NSCLC (any histology) with an Eastern Cooperative Oncology Group performance status of 0-1, any PD-L1 expression, and no EGFR mutations or ALK translocations, received carboplatin area under the curve (AUC) 6 day 1, nab-paclitaxel 100 mg/m2 days 1, 8, 15, and pembrolizumab 200 mg day 1 q21 days for 4 cycles followed by maintenance pembrolizumab q3w. Co-primary endpoints were progression-free survival (PFS) and overall response rate (ORR). Forty-six evaluable patients enrolled, 14 in phase I and 32 in phase II, from June 2015 to July 2018 with a median duration of follow-up of 35.4 months. Median time from enrollment to data lock was 42 months. In the ITT population, the ORR was 35%, median PFS was 5.6 months (95% CI, 4.6-8.2), and median OS was 15.4 months (CI, 12.4-28.1). There were no statistical differences in PFS or OS by PD-L1 status. The 2- and 3-year landmark OS rates were 33% and 24%, respectively. Carboplatin, nab-paclitaxel, and pembrolizumab are a safe and effective regimen for patients with both squamous and nonsquamous NSCLC. Although this study did not meet the prespecified endpoints, the median and landmark OS results are consistent with durable benefit of this regimen as seen in phase III trials for first-line treatment of advanced NSCLC.
- 30 June 2023
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 29 (1) , 47-56
Open AccessPhase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non–Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175
Combination chemotherapy and immunotherapy regimens have significantly improved survival for patients with previously untreated advanced non–small cell lung cancer (NSCLC). Improvements in overall survival (OS) in two separate pembrolizumab trials have demonstrated survival improvements over chemotherapy alone, regardless of PD-L1 status. The optimal chemotherapy backbone for combination with immunotherapy is unknown. We hypothesized nab-paclitaxel may be a well-suited platinum partner to use in combination with checkpoint inhibitor therapy for both adenocarcinoma and squamous histology and conducted a phase I/II trial to assess the efficacy of this regimen in advanced NSCLC. Adult patients with previously untreated, stage IIIB/IV NSCLC (any histology) with an Eastern Cooperative Oncology Group performance status of 0-1, any PD-L1 expression, and no EGFR mutations or ALK translocations, received carboplatin area under the curve (AUC) 6 day 1, nab-paclitaxel 100 mg/m2 days 1, 8, 15, and pembrolizumab 200 mg day 1 q21 days for 4 cycles followed by maintenance pembrolizumab q3w. Co-primary endpoints were progression-free survival (PFS) and overall response rate (ORR). Forty-six evaluable patients enrolled, 14 in phase I and 32 in phase II, from June 2015 to July 2018 with a median duration of follow-up of 35.4 months. Median time from enrollment to data lock was 42 months. In the ITT population, the ORR was 35%, median PFS was 5.6 months (95% CI, 4.6-8.2), and median OS was 15.4 months (CI, 12.4-28.1). There were no statistical differences in PFS or OS by PD-L1 status. The 2- and 3-year landmark OS rates were 33% and 24%, respectively. Carboplatin, nab-paclitaxel, and pembrolizumab are a safe and effective regimen for patients with both squamous and nonsquamous NSCLC. Although this study did not meet the prespecified endpoints, the median and landmark OS results are consistent with durable benefit of this regimen as seen in phase III trials for first-line treatment of advanced NSCLC.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Soy Isoflavone Supplementation for Breast Cancer Risk Reduction: A Randomized Phase II Trial
PDF file - 44K, Hormone and protein concentrations in nipple aspiration fluid (NAF) samples
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Soy Isoflavone Supplementation for Breast Cancer Risk Reduction: A Randomized Phase II Trial
PDF file - 44K, Hormone and protein concentrations in nipple aspiration fluid (NAF) samples
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Soy Isoflavone Supplementation for Breast Cancer Risk Reduction: A Randomized Phase II Trial
PDF file - 42K, Changes in cellular parameters for equol producers compared to control women, shown as the differences in post-intervention and baseline values
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Soy Isoflavone Supplementation for Breast Cancer Risk Reduction: A Randomized Phase II Trial
PDF file - 42K, Changes in cellular parameters for equol producers compared to control women, shown as the differences in post-intervention and baseline values
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Soy Isoflavone Supplementation for Breast Cancer Risk Reduction: A Randomized Phase II Trial
PDF file - 42K, Changes in cellular parameters for equol producers compared to control women, shown as the differences in post-intervention and baseline values
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Soy Isoflavone Supplementation for Breast Cancer Risk Reduction: A Randomized Phase II Trial
PDF file - 42K, Changes in cellular parameters for equol producers compared to control women, shown as the differences in post-intervention and baseline values
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Soy Isoflavone Supplementation for Breast Cancer Risk Reduction: A Randomized Phase II Trial
PDF file - 45K, Adverse events in soy and placebo groups
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Soy Isoflavone Supplementation for Breast Cancer Risk Reduction: A Randomized Phase II Trial
PDF file - 45K, Adverse events in soy and placebo groups
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Soy Isoflavone Supplementation for Breast Cancer Risk Reduction: A Randomized Phase II Trial
PDF file - 44K, Hormone and protein concentrations in nipple aspiration fluid (NAF) samples
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Soy Isoflavone Supplementation for Breast Cancer Risk Reduction: A Randomized Phase II Trial
PDF file - 44K, Hormone and protein concentrations in nipple aspiration fluid (NAF) samples